Skip to main content
Quest Diagnostics

Evolution and Co-Occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level

Evolution and Co-Occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level

Authors: Da Cruz Paula A, Zhu Y, Brown DN, Issa Bhaloo S, Pareja F, Hoang TJ, Green H, Basili T, Dopeso H, Selenica P, da Silva EM, Riaz N, Chandarlapaty S, Abu-Rustum NR, Reis-Filho JS, Weigelt B

Citation: Clin Cancer Res. 2025 Aug 20. doi: 10.1158/1078-0432.CCR-25-1237. Online ahead of print.

Specialties: Oncology

Related content

Test FAQ
AML Rapid Mutation Panel
Audio Podcast
Molecular Expression Through the Eyes of the Pathologist and Oncologist
Publication
Probing the Relevance of BRCA1 and BRCA2 Germline Pathogenic Variants Beyond Breast and Ovarian Cancer
Test FAQ
Comprehensive Hereditary Cancer Panel
Test FAQ
Guideline based Hereditary Cancer Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.